Redeye ceases its coverage of Pila Pharma due to the end of the contractual period.
Redeye leaves a short comment on Pila Pharma following the outcome of its rights issue which raised SEK6.
Redeye leaves its view on Pila Pharma following its report for the third quarter of 2022.
Redeye feels encouraged that the preclinical preparations of XEN-DIA keep progressing according to plan.
Redeye comments on Pila Pharma’s Q2 report. Highlights from the quarter include receiving ODD for XEN-D0501 and the commencement of the toxi...
Redeye leaves its comments on Pila Pharma following today’s uplifting news that the three-month preclinical toxicological studies have been ...
Redeye comments on Pila Pharma’s new pipeline announcement and adjusts its fair value range ahead of an anticipated capital injection.
Redeye leaves its comment on Pila Pharma following the announcement of its Q1 report.
Redeye leaves its comment on Pila Pharma following the announcement of its year-end report.
